BioSpace News Archive

BioMidwest

Sensus Healthcare Takes Order for 10 TransDermal Infusion Systems™ Supporting Hair Enhancement Centers Expansion Along with U.SK Under Skin’s Hair-Health Serum

Sensus Healthcare, Inc. announces the sale of 10 Transdermal Infusion Systems™ to Hair Enhancement Centers, a rapidly-growing chain of Texas-based hair loss treatment centers.

July 27, 2022
·
8 min read
BioMidwest

Daxor Corporation Announces a 49.4% Increase In Its Single-Use Diagnostic Kits Year-Over-Year and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.

Daxor Corporation announces an unaudited increase of 49.4% in sales of its single-use diagnostic kits by volume on a year-over-year basis, driven by a combination of the purchase and leasing of capital equipment, reference lab use, and the opening of twelve new commercial and academic accounts.

July 27, 2022
·
3 min read
Drug Development

Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the first patient has been screened in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.

July 27, 2022
·
4 min read
Drug Development

Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today announced new clinical data on safety, pharmacodynamics and anti-tumor activity from the Phase 1/2 ABILITY study of MDNA11, the Company’s long-acting IL-2 super agonist.

July 27, 2022
·
7 min read
Biotech Beach

Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.

Cidara Therapeutics, Inc. (Nasdaq: CDTX) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for rezafungin for the treatment of candidemia and invasive candidiasis.

July 27, 2022
·
9 min read
Origin Agritech Receives a $35 Million Order from Muyuan Foods

Origin Agritech Ltd., an agriculture technology company, announced that the company has received an order for its hybrid corn worth RMB240 million, or roughly $35 million, from Muyuan Foods.

July 27, 2022
·
4 min read
Business

Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.

Melinta Therapeutics, LLC (“Melinta”) and Cidara Therapeutics (“Cidara”) today announced that they have entered into a License Agreement (the “Agreement”) to facilitate a strategic partnership to commercialize rezafungin, a novel, once-weekly echinocandin antifungal in the United States (U.S.).

July 27, 2022
·
6 min read
Business

Agilent 2022 Early Career Professor Award Presented to Stefanos Nikolaidis

Agilent Technologies Inc. (NYSE: A) announced today that Stefanos Nikolaidis Ph.D. has received the Agilent 2022 Early Career Professor Award.

July 27, 2022
·
3 min read
Biotech Bay

180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the NIHR in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program With 180 Life Sciences Corp.

180 Life Sciences Corp. announced that a team led by researchers at University of Oxford have been awarded a grant from the National Institute for Health and Care Research in the U.K. to conduct a feasibility trial to investigate whether anti-tumor necrosis factor therapy, administered at the time of surgery, can reduce or prevent post operative delirium/cognitive deficit.

July 27, 2022
·
12 min read